Our mission is to educate and inspire farmers, ranchers, and consumers about the importance of sustainability, regenerative farming, and biodiversity in our food systems.

Pork has long been scrutinized for its high linoleic acid content, but there is now an even bigger reason to avoid it. Pork producers have been using customizable mRNA-based "vaccines" on their herds since 2018, which has gone unnoticed by many. This gene therapy for pigs has raised concerns about the potential dangers of consuming meat that has undergone this treatment.

According to Merck's animal health website, the Sequivity vaccine platform harnesses RNA particle technology to create customized prescription vaccines against strains of influenza A virus in swine, porcine circovirus (PCV), rotavirus, and beyond. This vaccine only targets swine pathogen gene sequences of interest, does not replicate or cause disease, and delivers pathogen information to the immune system. It also allows for the creation of multivalent formulations by blending RNA particles to target multiple swine pathogens in one shot.

While Merck was not alone in developing veterinary mRNA shots, they acquired the company that developed the very first RNA-based livestock vaccine, a swine influenza (H3N2) RNA shot, which was licensed in 2012. In 2015, they followed up with an avian influenza mRNA shot. CureVac developed an mRNA-based rabies shot for pigs in 2016, while Bayer partnered with BioNTech to develop mRNA "vaccines" for both livestock and pets, although they did not launch anything.

Americans have been eating pork treated with gene therapy for the past five years, and even more of our meat supply is about to get contaminated with the same treatment. In addition to the avian influenza RNA shot for chickens licensed in 2015, newer mRNA-lipid nanoparticle shots for avian influenza are also in the works. Iowa State University is also working on an mRNA shot for cows, and lobbyists for the Cattlemen's Association recently confirmed they intend to use mRNA "vaccines" in cattle, which might affect both dairy and beef.

Sequivity, introduced in 2018, was one of the products that came out of Merck's partnership with Moderna. Sequivity is not so much a single vaccine as it is a platform that can be endlessly customized, all without additional safety analyses over and beyond the initial testing. According to Zoetis, the largest producer of veterinary drugs and vaccines, Sequivity has safety and efficacy studies based on the platform with a historical initial isolate, not likely the isolate that customers would be requesting in their product.

The process of customizing the Sequivity vaccine involves collecting the pathogen, sending it to a diagnostic lab, sequencing the gene of interest, synthesizing a version of the gene of interest, and formulating RNA particles into a customized "vaccine." A customized "vaccine" can be created in as little as eight weeks. This process raises concerns about the potential risks of consuming meat treated with this gene therapy.

In conclusion, the use of mRNA-based "vaccines" on livestock is an issue that requires further examination. With gene therapy being used to create custom vaccines for pigs, cows, and even chickens, the long-term effects of consuming meat that has undergone this treatment remain unknown. While the creation of these vaccines is meant to be a solution to animal diseases, it is crucial to consider the potential risks and to prioritize the safety of both animals and humans.